keyword
MENU ▼
Read by QxMD icon Read
search

naltrexon

keyword
https://www.readbyqxmd.com/read/29460668/personal-control-over-decisions-to-participate-in-research-by-persons-with-histories-of-both-substance-use-disorders-and-criminal-justice-supervision
#1
Donna T Chen, Tomohiro M Ko, Ashleigh A Allen, Richard J Bonnie, Colleen E Suratt, Paul S Appelbaum, Edward V Nunes, Peter D Friedmann, Joshua D Lee, Michael S Gordon, Ryan McDonald, Donna Wilson, Tamara Y Boney, Sean M Murphy, Charles P O'Brien
Individuals must feel free to exert personal control over decisions regarding research participation. We present an examination of participants' perceived personal control over, as well as reported pressures and threats from others, influencing their decision to join a study assessing the effectiveness of extended-release naltrexone in preventing opioid dependence relapse. Most participants endorsed a strong sense of control over the decision; few reported pressures or threats. Although few in number, participants' brief narrative descriptions of the pressures and threats are illuminating and provide context for their perceptions of personal control...
February 1, 2018: Journal of Empirical Research on Human Research Ethics: JERHRE
https://www.readbyqxmd.com/read/29445297/managing-severe-pain-and-abuse-potential-the-potential-impact-of-a-new-abuse-deterrent-formulation-oxycodone-naltrexone-extended-release-product
#2
REVIEW
Joseph V Pergolizzi, Robert Taylor, Jo Ann LeQuang, Robert B Raffa
Proper management of severe pain represents one of the most challenging clinical dilemmas. Two equally important goals must be attained: the humanitarian/medical goal to relieve suffering and the societal/legal goal to not contribute to the drug abuse problem. This is an age-old problem, and the prevailing emphasis placed on one or the other goal has resulted in pendulum swings that have resulted in either undertreatment of pain or the current epidemic of misuse and abuse. In an effort to provide efficacious strong pain relievers (opioids) that are more difficult to abuse by the most dangerous routes of administration, pharmaceutical companies are developing products in which the opioid is manufactured in a formulation that is designed to be tamper resistant...
2018: Journal of Pain Research
https://www.readbyqxmd.com/read/29441714/time-dependent-regional-brain-distribution-of-methadone-and-naltrexone-in-the-treatment-of-opioid-addiction
#3
Belin G Teklezgi, Annapurna Pamreddy, Sooraj Baijnath, Hendrik G Kruger, Tricia Naicker, Nirmala D Gopal, Thavendran Govender
Opioid addiction is a serious public health concern with severe health and social implications; therefore, extensive therapeutic efforts are required to keep users drug free. The two main pharmacological interventions, in the treatment of addiction, involve management with methadone an mu (μ)-opioid agonist and treatment with naltrexone, μ-opioid, kappa (κ)-opioid and delta (δ)-opioid antagonist. MET and NAL are believed to help individuals to derive maximum benefit from treatment and undergo a full recovery...
February 14, 2018: Addiction Biology
https://www.readbyqxmd.com/read/29441516/detection-of-naltrexone-and-naltrexol-in-patients-prescribed-embeda%C3%A2
#4
Robert West, Maria Guevara, Charles Mikel
No abstract text is available yet for this article.
May 2017: Journal of Opioid Management
https://www.readbyqxmd.com/read/29438157/effects-of-varenicline-alone-and-in-combination-with-low-dose-naltrexone-on-alcohol-primed-smoking-in-heavy-drinking-tobacco-users-a-preliminary-laboratory-study
#5
Walter Roberts, Julia M Shi, Jeanette M Tetrault, Sherry A McKee
OBJECTIVES: Heavy-drinking tobacco users are less likely to successfully quit smoking than their moderate-drinking counterparts, even when they are prescribed smoking cessation medication. One strategy for improving treatment outcomes in this subgroup of tobacco users may be to combine medication therapies to target both alcohol and tobacco use simultaneously. Adding naltrexone to frontline smoking cessation treatments may improve treatment outcomes in this group. METHOD: This double-blind, placebo-controlled human laboratory study examined the effects of varenicline (2 mg/d) and varenicline (2 mg/d), combined with a low dose of naltrexone (25 mg/d) on alcohol-primed smoking behavior in a laboratory model of smoking relapse in heavy-drinking tobacco users (n = 30)...
February 12, 2018: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/29436984/effectiveness-of-pharmacological-or-psychological-interventions-for-smoking-cessation-in-smokers-with-major-depression-or-depressive-symptoms-a-systematic-review-of-the-literature
#6
Giulia A Aldi, Giuly Bertoli, Francesca Ferraro, Aldo Pezzuto, Fiammetta Cosci
BACKGROUND: Smokers with major depressive disorder (MDD) or depressive symptoms (DS) represent a subgroup in need of attention since they have specific clinical features and prognosis. METHODS: A systematic review of the literature (Cochrane, MEDLINE, ScienceDirect, Web Of Science databases from inception to June 2017) of randomized clinical trials assessing the effectiveness of pharmacological, psychological or combined interventions for smoking cessation in subjects with current or past MDD/DS without medical or comorbid psychiatric disorder(s) was run following the PRISMA guidelines...
February 13, 2018: Substance Abuse
https://www.readbyqxmd.com/read/29431852/nicotine-use-smoking-is-associated-with-the-efficacy-of-naltrexone-in-the-treatment-of-alcohol-dependence
#7
Raymond F Anton, Patricia K Latham, Konstantin E Voronin, Patrick K Randall, Sarah W Book, Michaela Hoffman, Joseph P Schacht
BACKGROUND: The opioid antagonist naltrexone is not efficacious for every alcohol treatment seeker. However, various individual factors, such as genetic differences and nicotine-use/smoking status, have been suggested as predictors of naltrexone response. In a randomized clinical trial, we previously reported that nicotine-use/smoking status might be a stronger predictor of naltrexone efficacy than OPRM1 A118G single nucleotide polymorphism (SNP) genotype. In this report, we further characterize the nicotine-users in that trial, examine other drinking outcomes, examine the influence of smoking change on naltrexone effects on drinking, and validate the result in smokers with disialo carbohydrate-deficient transferrin (%dCDT) change as an independent biomarker of response...
February 12, 2018: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/29422496/opioid-antagonists-and-the-a118g-polymorphism-in-the-%C3%AE-opioid-receptor-gene-effects-of-gsk1521498-and-naltrexone-in-healthy-drinkers-stratified-by-oprm1-genotype
#8
Hisham Ziauddeen, Liam J Nestor, Naresh Subramaniam, Chris Dodds, Pradeep J Nathan, Sam R Miller, Bhopinder K Sarai, Kay Maltby, Disala Fernando, Liling Warren, Louise K Hosking, Dawn Waterworth, Anna Korzeniowska, Beta Win, Duncan B Richards, Lakshmi Vasist Johnson, Paul C Fletcher, Edward T Bullmore
This corrects the article DOI: 10.1038/npp.2016.60.
March 2018: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29420073/open-label-pilot-study-of-injectable-naltrexone-for-cannabis-dependence
#9
Daniel P Notzon, Meredith A Kelly, C Jean Choi, Martina Pavlicova, Amy L Mahony, Daniel J Brooks, John J Mariani, Frances R Levin
BACKGROUND: There are no FDA-approved pharmacotherapies for cannabis use disorders (CUD), despite the evaluation of numerous medications. Notably, chronic dosing of oral naltrexone decreases self-administration of cannabis in human laboratory studies. OBJECTIVES: To test the feasibility of long-acting injectable naltrexone for the treatment of CUD, while obtaining preliminary safety and efficacy data. METHODS: Twelve adult participants (seven male) meeting DSM-IV-TR criteria for cannabis dependence enrolled into an 8-week, open-label pilot study conducted at an academic treatment research clinic...
February 8, 2018: American Journal of Drug and Alcohol Abuse
https://www.readbyqxmd.com/read/29415856/a-qualitative-assessment-of-attitudes-about-and-preferences-for-extended-release-naltrexone-a-new-pharmacotherapy-to-treat-opioid-use-disorders-in-ukraine
#10
Ruthanne Marcus, Martha J Bojko, Alyona Mazhnaya, Iuliia Makarenko, Sergii Filippovych, Sergii Dvoriak, Frederick L Altice, Sandra A Springer
Numerous individual barriers, including negative attitudes toward opioid agonist therapies (OAT), have undermined HIV prevention efforts in Ukraine where the epidemic is concentrated in people who inject drugs (PWID). The recent availability of extended-release naltrexone (XR-NTX), an opioid antagonist, provides new opportunities for treatment and prevention, but little is known about patient preferences. We conducted qualitative analysis using focus groups (FG) of PWID recruited based on OAT experience: currently, previously, and never on OAT in five Ukrainian cities...
March 2018: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/29415846/associations-between-pharmacotherapy-for-opioid-dependence-and-clinical-and-criminal-justice-outcomes-among-adults-with-co-occurring-serious-mental-illness
#11
Allison G Robertson, Michele M Easter, Hsiu-Ju Lin, Linda K Frisman, Jeffrey W Swanson, Marvin S Swartz
Adults suffering from a serious mental illness (SMI) and a substance use disorder are at especially high risk for poor clinical outcomes and also arrest and incarceration. Pharmacotherapies for treating opioid dependence could be a particularly important mode of treatment for opioid-dependent adults with SMI to lower their risk for overdose, high-cost hospitalizations, repeated emergency department visits, and incarceration, given relapse rates are very high following detoxification in the absence of one of the three FDA-approved pharmacotherapies...
March 2018: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/29408463/bupropion-and-naltrexone-combination-alters-high-fructose-corn-syrup-self-administration-and-gene-expression-in-rats
#12
AnneMarie Levy, Stephen Daniels, Roger Hudson, Thomas Horman, Amanda Flynn, Yan Zhou, Francesco Leri
Contrave® is an adjunct pharmacotherapy for obesity that contains bupropion (BUP) and naltrexone (NTX). To further explore the psychopharmacology of this drug combination, male Sprague-Dawley rats were implanted with subcutaneous osmotic mini-pumps releasing: 40 mg/kg/day BUP, 4 mg/kg/day NTX, or 40 + 4 mg/kg/day BUP and NTX (BN). During 12 days of exposure, the animals were tested on operant intraoral self-administration (IOSA) of high fructose corn syrup (HFCS) on continuous (FR1) and progressive ratio (PR) schedules, on home cage drinking of HFCS, and on HFCS taste reactivity...
February 2, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29404882/the-peripheral-corticotropin-releasing-factor-crf-induced-analgesic-effect-on-somatic-pain-sensitivity-in-conscious-rats-involving-crf-opioid-and-glucocorticoid-receptors
#13
REVIEW
Natalia I Yarushkina, Ludmila P Filaretova
The corticotropin-releasing factor (CRF) is involved in somatic pain regulation and may produce an analgesic effect in humans and animals, although the mechanisms of the CRF-induced analgesia remain unclear. CRF action is mediated by the CRF receptors of subtypes 1 and 2 (CRF-R1 and CRF-R2, respectively). Activation of the hypothalamic -pituitary -adrenocortical axis (HPA) is provided by CRF-R1; but CRF-R2 are also involved in the regulation of the HPA axis, and, respectively, glucocorticoids, the end hormones of the HPA axis, also participate in somatic pain regulation...
February 5, 2018: Inflammopharmacology
https://www.readbyqxmd.com/read/29396985/extended-release-injectable-naltrexone-for-opioid-use-disorder-a-systematic-review
#14
REVIEW
Brantley P Jarvis, August F Holtyn, Shrinidhi Subramaniam, D Andrew Tompkins, Emmanuel A Oga, George E Bigelow, Kenneth Silverman
AIMS: To review systematically the published literature on extended-release naltrexone (XR-NTX, Vivitrol®), marketed as a once-per-month injection product to treat opioid use disorder. We addressed the following questions: (1) How successful is induction on XR-NTX?; (2) What are adherence rates to XR-NTX?; and (3) Does XR-NTX decrease opioid use? Factors associated with these outcomes as well as overdose rates were examined. METHODS: We searched PubMed and used Google Scholar for forward citation searches of peer-reviewed articles from January 2006 to June 2017...
February 3, 2018: Addiction
https://www.readbyqxmd.com/read/29395188/real-time-assessment-of-alcohol-craving-and-naltrexone-treatment-responsiveness-in-a-randomized-clinical-trial
#15
Robert Miranda, Hayley Treloar Padovano, Joshua C Gray, Stephanie E Wemm, Alexander Blanchard
INTRODUCTION: This secondary data analysis examined whether and how the dopamine receptor D4 gene (DRD4) influenced naltrexone treatment responsiveness in a randomized clinical trial. We leveraged intensive experience sampling methods to test the hypothesis that craving recorded at drinking and non-drinking moments would mediate naltrexone effects on the likelihood of heavy drinking, but only among carriers of the DRD4 long (DRD4-L) allele. METHODS: Participants (Mage=29...
January 10, 2018: Addictive Behaviors
https://www.readbyqxmd.com/read/29391826/spotlight-on-naldemedine-in-the-treatment-of-opioid-induced-constipation-in-adult-patients-with-chronic-noncancer-pain-design-development-and-place-in-therapy
#16
REVIEW
Emily K Stern, Darren M Brenner
Opioid-induced constipation (OIC) is an increasingly prevalent problem in the USA due to the growing use of opioids. A novel class of therapeutics, the peripherally acting μ-opioid receptor antagonists (PAMORAs), has been developed to mitigate the deleterious effects of opioids in the gastrointestinal tract while maintaining central analgesia and minimizing opioid withdrawal. This review aimed to summarize the literature on naldemedine, the third PAMORA to gain US Food and Drug Administration (FDA) approval for the treatment of OIC in adults with chronic noncancer pain-related syndromes...
2018: Journal of Pain Research
https://www.readbyqxmd.com/read/29388462/safety-and-tolerability-of-new-generation-anti-obesity-medications-a-narrative-review
#17
Dhiren K Patel, Fatima Cody Stanford
The prevalence of obesity and associated comorbidities is rising. Despite their weight-loss efficacy, new generation anti-obesity medications are only prescribed to a minority of adults with obesity, possibly, which in part may be due to safety concerns. This review presents detailed safety profiles for orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion and liraglutide 3.0 mg, and discusses the associated risk-benefit profiles. Two anti-obesity medications presented safety issues that warranted further discussion; phentermine/topiramate (fetal toxicity) and liraglutide 3...
February 8, 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29385430/the-effect-of-low-dose-naltrexone-on-medication-in-inflammatory-bowel-disease-a-quasi-experimental-before-and-after-prescription-database-study
#18
Guttorm Raknes, Pia Simonsen, Lars Småbrekke
Background and Aims: Low dose naltrexone (LDN) is a controversial off-label treatment used by many Crohn's disease (CD) and ulcerative colitis (UC) patients. A small number of preliminary studies indicate that LDN might be beneficial in CD, but evidence is too scarce to demonstrate efficacy. We wanted to examine whether initiation of LDN therapy by patients with inflammatory bowel disease (IBD) was followed by changes in dispensing of relevant medication. Methods: We performed a quasi-experimental before and after study following a sudden increase of LDN use in the Norwegian population in 2013...
January 27, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29377216/the-safety-and-efficacy-of-low-dose-naltrexone-in-the-management-of-chronic-pain-and-inflammation-in-multiple-sclerosis-fibromyalgia-crohn-s-disease-and-other-chronic-pain-disorders
#19
Denise K Patten, Bob G Schultz, Daniel J Berlau
Chronic inflammatory diseases are complex to treat and have an impact on a large number of patients. Due to the difficulty of treating these diseases and the great impact on quality of life, patients often seek off-label, complimentary, or alternative medicines to gain relief from symptoms. Low-dose naltrexone has been used off-label for treatment of pain and inflammation in multiple sclerosis, Crohn's disease, fibromyalgia, and other diseases. Naltrexone is a mu-opioid receptor antagonist indicated by the Food and Drug Administration for opioid and alcohol dependence...
January 27, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29376439/pharmacotherapy-for-obesity-in-individuals-with-type-2-diabetes
#20
Tariq Chukir, Alpana P Shukla, Katherine H Saunders, Louis J Aronne
Type 2 diabetes (T2DM) is associated with significant morbidity and mortality. Obesity is one of the main risk factors for T2DM and its management requires a multidisciplinary approach, which may include pharmacotherapy. Areas covered: In this paper, data on efficacy, tolerability and safety of FDA-approved pharmacotherapies for obesity (orlistat, phentermine/topiramate extended-release, lorcaserin, bupropion sustained release/naltrexone sustained release and liraglutide) are reviewed, focusing on individuals with type 2 diabetes...
January 29, 2018: Expert Opinion on Pharmacotherapy
keyword
keyword
88617
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"